Study of the effectiveness and safety of the sequential use of Mexidol and Mexidol Forte 250 in the treatment of patients with acute ischemic stroke

Authors:
S.M. KARPOV¹, M.Yu. MOROZOVA², K.A. MURAVYEV², I.A. VYSHLOVA¹, F.S. KANTEMIROVA³

¹Federal State Educational Institution of Higher Education "Stavropol State Medical University" of the Ministry of Health of the Russian Federation, Stavropol, Russia;
²Municipal Budgetary Healthcare Institution "City Clinical Hospital No. 3", Stavropol, Russia;
³ Institute "Medical Academy named after S.I. Georgievsky" of the Federal State Autonomous Educational Institution of Higher Education "Crimean Federal University named after V.I. Vernadsky", Simferopol, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2022, Vol. 122, No. 3, Issue 2

Abstract:
The aim of the study was to evaluate the efficacy of Mexidol for restoring cognitive function in patients after ischemic stroke (IS).

Material and methods. Seventy patients with acute ischemic stroke were examined and randomly assigned to two groups. Group 1 consisted of 40 patients (28 men, 12 women) who, along with standard therapy, received Mexidol 500 mg/day intravenously by drip for 14 days, followed by oral administration of Mexidol Forte 250 750 mg/day for 60 days. Group 2 included 30 patients (21 men, 9 women) who received standard therapy alone.

Results. Baseline scores on the MoCA and MMSE scales did not differ between the two groups. Retesting showed that improvements on these scales were statistically more significant in Group 1. Analysis of the P300 evoked potential confirmed a more pronounced positive trend in Group 1 (p

Conclusion: Sequential Mexidol therapy results in more complete recovery of cognitive function in patients who have suffered a stroke.

Key words: stroke, acute cerebrovascular accident, cognitive impairment, Mexidol, Mexidol Forte 250.